10 pending office actions • 5 clients
| App # | Title | Client | Examiner | Art Unit | Status | Filed |
|---|---|---|---|---|---|---|
| 18691500 | KCa3.1 INHIBITORS FOR PODOCYTE PROTECTION | Long Island University | SZNAIDMAN, MARCOS L | 1628 | Non-Final OA | Mar 13, 2024 |
| 18548348 | BENZOXAZOLONE INHIBITORS OF INFLAMMASOMES | The United States Department of Veterans Affairs | HEASLEY, MEGHAN CHRISTINE | 1626 | Non-Final OA | Aug 30, 2023 |
| 18547930 | METHOD FOR DECREASING DEGENERATION OF RETINAL GANGLION CELLS | Icahn School Of Medicine AT Mount Sinai | SU-TOBON, QIWEN NMN | 1636 | Non-Final OA | Aug 25, 2023 |
| 18349494 | REGULATORY SYSTEM FOR EXPRESSION OF A GENE OF INTEREST IN A TARGET CELL AND METHOD OF USE THEREOF | Icahn School Of Medicine AT Mount Sinai | WARD, AARON DUREL | 1636 | Non-Final OA | Jul 10, 2023 |
| 18001516 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | Icahn School Of Medicine AT Mount Sinai | CHEN, PO-CHIH | 1621 | Non-Final OA | Dec 12, 2022 |
| 17997616 | COMPOSITIONS AND METHODS FOR PREVENTING, DETECTING, AND TREATING INFLAMMATORY BOWEL DISEASE | The Governing Council of the University of Toronto | MCCOLLUM, ANDREA K | 1674 | Non-Final OA | Oct 31, 2022 |
| 17775707 | GENE DELIVERY SYSTEMS FOR TREATMENT OF HEART FAILURE | Icahn School Of Medicine AT Mount Sinai | KIM, TAEYOON | 1631 | Final Rejection | May 10, 2022 |
| 17753708 | ANC80 ENCODING SPHINGOLIPID-METABOLIZING PROTEINS FOR MITIGATING DISEASE-INDUCED TISSUE DAMAGE | Icahn School Of Medicine AT Mount Sinai | PAULUS, ERIN VIRGINIA | 1631 | Non-Final OA | Mar 11, 2022 |
| 17753660 | COMPOSITIONS INCLUDING MOLECULES OF MODIFIED MRNA AND METHODS OF USING THE SAME | Icahn School Of Medicine AT Mount Sinai | SINGH, ANOOP KUMAR | 1632 | Non-Final OA | Mar 10, 2022 |
| 17045256 | COMPOSITIONS AND METHODS OF TREATMENT OF VISION LOSS THROUGH GENERATION OF ROD PHOTORECEPTORS FROM MÜLLER GLIAL CELLS | Icahn School Of Medicine AT Mount Sinai | STAVROU, CONSTANTINA E | 1632 | Final Rejection | Oct 05, 2020 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial